PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
Zacks Investment Research10/5/2026Positive
PGEN
Precigen IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.29B
P/E Ratio
—
EPS
$-1.04
Beta
0.92
52W High
$8.98
52W Low
$3.04
50-Day MA
$7.30
200-Day MA
$5.17
Dividend Yield
—
Profit Margin
-184.00%
Forward P/E
16.89
PEG Ratio
—
About Precigen Inc
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
Fundamentals
| Revenue (TTM) | $85.72M |
| Gross Profit (TTM) | $45.44M |
| EBITDA | $-35.36M |
| Operating Margin | 41.20% |
| Return on Equity | -837.00% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $0.25 |
| Book Value | $0.12 |
| Price-to-Book | 61.05 |
| Price-to-Sales (TTM) | 26.67 |
| EV/Revenue | 31.74 |
| EV/EBITDA | -3.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 6323.00% |
| Shares Outstanding | $358.04M |
| Float | $194.60M |
| % Insiders | 12.64% |
| % Institutions | 73.06% |
Historical Volatility
HV 10-Day
72.20%
HV 20-Day
71.49%
HV 30-Day
65.73%
HV 60-Day
63.08%
HV Rank
31.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($13.65 target)
1
Strong Buy1
Buy1
HoldLatest News
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Zacks Investment Research10/2/2026Neutral
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Investment Research10/1/2026Positive
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Zacks Investment Research9/30/2026Positive
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
Precigen just received an FDA "platform technology designation" for AdenoVerse, something that validates its versatility and accelerates its pipeline. PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP with rapid payer coverage and strong uptake. PGEN targets a $2B peak global sales opportunity, with EMA approval for PAPZIMEOS potentially doubling the addressable market by year-end or early 2027.
Seeking Alpha9/30/2026Positive
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
Zacks Investment Research9/24/2026Positive
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®.
PRNewsWire9/21/2026Neutral
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
Zacks Investment Research9/14/2026Positive
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
Zacks Investment Research9/10/2026Positive
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Zacks Investment Research8/27/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PGEN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 10/17/2026